Background of Pfizer Inc
Pfizer Inc is an American multinational pharmaceutical corporation headquartered in New York City, and is one of the world’s largest pharmaceutical companies.
The company is listed on the New York Stock Exchange, and its shares have been a component of the Dow Jones Industrial Average since 2004. Pfizer ranked No. 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.
Pfizer Inc has a history dating back to 1849 when it was first established as a chemicals business, operating as Charles Pfizer and Company, and Bartlett Street in Williamsburg, Brooklyn, where it produced an antiparasitic called santonin.
This was an immediate success, although it was the production of citric acid that led to Pfizer’s growth in the 1880s. Pfizer continued to buy property to expand its lab and factory.
By the 1950s, Pfizer had established offices in Belgium, Brazil, Canada, Cuba, Mexico, Panama, Puerto Rico, and the United Kingdom.
In 1960, the company moved its medical research laboratory operations out of New York City to a new facility in Groton, Connecticut.
In 1980, the company launched Feldene (piroxicam), a prescription anti-inflammatory medication that became Pfizer’s first product to reach one billion dollars in total sales.
During the 1980s and 1990s, Pfizer Corporation growth was sustained by the discovery and marketing of Zoloft, Lipitor, Norvasc, Zithromax, Aricept, Diflucan, and Viagra.
In 2003, the company acquired Esperion Therapeutics for $1.3 billion (later selling the unit in 2008).
In 2004, Pfizer announced it would acquire Meridica for $125 million. In 2005, the company acquired Vicuron Pharmaceuticals for $1.9 billion, Idun for just less than $300 million and finally Angiosyn for $527 million.
Today, the company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.
It’s high-value product portfolio includes the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug.
Pfizer Inc Growth Driver
As a leading pharmaceutical developer and supplier, Pfizer Inc is well positioned to provide a resilient response to the economic contraction resulting from the global coronavirus crisis.
The company consistently and diligently monitors the supply of its medicines. Pfizer operates one of the most sophisticated supply chain systems in the industry, with more than 40 Pfizer-owned sites and more than 200 suppliers globally, which provides capacity and redundancy as needed.
The company’s manufacturing and supply chain professionals have been working non-stop to ensure that the global supply of Pfizer medicines continue to be available to patients.
As of now, the company has not seen a significant disruption in its supply chain, and all of its manufacturing sites around the world have continued to operate at or near normal levels.
Nonetheless, the company has implemented an unprecedented and comprehensive preparedness plan to control its site operations and will continue to provide timely updates if there is any new information to be shared.
As part of this preparedness plan, the company has in fact increased production, shifted demand to the most critical products, and authorized overtime at many sites to meet patient needs, as well as taking a number of steps simultaneously to scale up manufacturing operations at risk to accelerate its ability to supply a potential novel treatment or vaccine for COVID-19.
The company has also implemented an enhanced demand monitoring and order management process and instituted a heightened logistics control program to ensure its products get from its sites to its customers.
Furthermore, as part of this COVID-19 strategy, the company expects to start a clinical study of a potential antiviral molecule for SARS-CoV-2.
As part of its COVID-19 efforts, Pfizer is working on an agreement with the Liverpool School of Tropical Medicine to fund and support two new studies that will focus on the interaction between Streptococcus pneumoniae — bacteria that cause pneumococcal pneumonia — and the novel coronavirus.
As such, the company’s strong manufacturing and supply chain model, coupled with a high-value pharmaceuticals portfolio, places it in a prime position to deliver growth for all of it stakeholders.
If the company’s vaccine trials prove successful, the results could pay dividends for investors.
Pfizer Inc Investor Tip
Pfizer Inc trades on the New York Stock Exchange (NYSE) where investors can buy shares under the stock symbol PFE
Data from the company’s 2025 financial analysis of its fiscal first quarter results shows Revenues Declined only 1% Operationally, with a 12% Operational Growth from Biopharma, Primarily Driven by Eliquis, Vyndaqel/Vyndamax, Ibrance and Inlyta as well as 15% Operational Growth in Emerging Markets.
As a result of the lower number of in-person meetings with prescribers and restrictions on patient movements due to government-mandated work-from-home or shelter-in-place policies, the rate of new prescriptions for certain products and of vaccination rates for most vaccines has slowed, which is currently expected to primarily impact second-quarter 2025 financial results.
These declines are expected to be partially offset by existing patients refilling prescriptions that extend the per-prescription treatment duration to avoid going to pharmacies as frequently, which had a modest favourable impact in first-quarter 2025 and is expected to continue in second-quarter 2025.
In addition, certain Pfizer medicines saw increased demand, which Pfizer believes may be due to physicians apparently prescribing them to treat or prevent COVID-19 infections or related conditions.
Due to Pfizer’s significant operating cash flows, as well as its financial assets, access to capital markets and revolving credit agreements, Pfizer believes it has, and will maintain, the ability to meet liquidity needs for the foreseeable future.
Pfizer will continue to pursue efforts to maintain the continuity of its operations while monitoring for new developments related to the COVID-19 pandemic, which are unpredictable. Future COVID-19 developments could result in additional favorable or unfavorable impacts on Pfizer’s business, operations or financial condition.
As such, the company has delivered a stable performance despite slight losses sustained due to the reduction in representative contact. However, the company remains in a strong position to benefit from the increased need for pharmaceuticals during the crisis, while the possible contributions of its vaccine trials to its stock value is yet to be determined.
All in all, indications show that the company should provide a rising share price for investors who choose to purchase shares today, securing a good long-term buy-in in 2025 and in the future.
Pfizer Inc Shareholders
Sector
Healthcare
Industry
Biotech & Pharma
Sub Industry
Large Pharma
How to buy Pfizer Inc Shares
1. Navigate to the AvaTrade website and select ‘Register’
2. Complete the registration form with the required information and submit documentation to verify your proof of Identity along with your proof of address.
3. As soon as your account application has been reviewed and approved, you can select your trading platform from AvaTrade’s website, or by visiting the MetaTrader 4 or MetaTrader 5 websites respectively to start download.
4. Once you have downloaded the trading platform of your choice, you can use your AvaTrade live account details to log into your AvaTrade account on the trading platform.
5. From the Market Watch screen on both MetaTrader 4 and MetaTrader 5, you can select AvaTrade to buy/purchase shares.
6. Alternatively, you can make use of AvaTrade’s online Web Trader or the AvaTradeGo mobile application.Buying shares has never been this convenient and easy. #myfirstshare
Trading CFDs and Stocks with AvaTrade provides traders with the following benefits
- Leverage of up to 1:20
- Being able to trade stocks on the NYSE, NASDAQ, FTSE, and various others.
- Indices, stocks, and commodities can all be traded form a single screen.
- Client support is presented live in a multitude of languages.
- Traders have exclusive access to a variety of educational tools
- Trades can be executed across multiple platforms
More shares that can be purchased / traded through AvaTrade, can be viewed here.
FAQ
- Can I buy Pfizer Inc shares in South Africa?
Yes, you can.
- How to buy Pfizer Inc shares
By simply opening a free account on SA Shares, or by clicking the “Buy this Share” button to get started.
- What is the current share price?
By clicking on the link provided above, you can view the real-time Pfizer Inc share price on the platform.
- Is Pfizer Inc a good share to buy?
Yes, while Pfizer Inc sustained slight losses in the first quarter of 2025, the company’s strong supply chain coupled with increasing demand for Covod19-related pharmaceutical treatments have delivered a stable performance. The company’s vaccine trials, if proven positive, could create a strong incentive to buy shares. As such, this company should be monitored by potential investors seeking long-term returns.
- Can I buy Pfizer Inc CFD through SA Shares?
Yes, you can.
- Can I buy Pfizer Inc shares in South Africa?